1.80
2.70%
-0.05
After Hours:
1.80
Aptorum Group Ltd stock is traded at $1.80, with a volume of 46,254.
It is down -2.70% in the last 24 hours and down -39.80% over the past month.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
See More
Previous Close:
$1.85
Open:
$1.82
24h Volume:
46,254
Relative Volume:
3.07
Market Cap:
$9.80M
Revenue:
$1.20M
Net Income/Loss:
$-2.82M
P/E Ratio:
-0.6626
EPS:
-2.7164
Net Cash Flow:
$-7.73M
1W Performance:
-11.98%
1M Performance:
-39.80%
6M Performance:
-81.03%
1Y Performance:
-20.53%
Aptorum Group Ltd Stock (APM) Company Profile
Aptorum Group Ltd Stock (APM) Latest News
Aptorum Group Limited (NASDAQ:APM) Sees Large Growth in Short Interest - Defense World
Aptorum Group Limited (NASDAQ:APM) Short Interest Down 47.1% in July - Defense World
Aptorum Group Limited (NASDAQ:APM) Short Interest Update - Defense World
Aptorum Group (NASDAQ:APM) Trading Up 0.4% - Defense World
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update30.04.2024 - wallstreet:online
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
symbol__ Stock Quote Price and Forecast - CNN
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid ... - Markets Insider
Nasdaq Rises 100 Points; BJ's Wholesale Posts Weak Sales - Benzinga
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a ... - sharewise
5 Investors Betting Big on Aptorum (APM) Group - InvestorPlace
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023 - Business Wire
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets - Yahoo Finance
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development - Marketscreener.com
Why Is Aptorum (APM) Stock Down 16% Today? - InvestorPlace
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group - Business Wire
Aptorum Group Announces 1-for-10 Reverse Stock Split - Business Wire
Cotações de Ações Americanas (STOCKS) - Money Times
DelveInsight Estimates a Promising Picture of Obesity Pipeline Space Landscape as Key 100+ Pharma Companies Working in the Space - PR Newswire
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics - ACROFAN
Notice to Boustead Securities Customers Who Purchased IPOs - GlobeNewswire
NY-APTORUM-GROUP-LIMITED | Business Wire - Via Ritzau
Aptorum Gr (NASDAQ:APM) Stock Quotes, Forecast and News Summary - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
42 Stocks Moving in Thursday's Pre-Market SessionC3.ai (NYSE:AI) - Benzinga
40 Stocks Moving in Monday's Pre-Market SessionAMC Enter Hldgs (NYSE:AMC), Aptorum Gr (NASDAQ:APM) - Benzinga
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 - businesswire.com
Aptorum Group Limited (NASDAQ:APM) Unveils Infectious Disease Liquid Biopsy Subsidiary to Co-develop RPIDD Tech - BP Journal
45 Stocks Moving in Wednesday's Pre-Market SessionAdial Pharmaceuticals (NASDAQ:ADIL), Aptorum Gr (NAS - Benzinga
33 Stocks Moving in Tuesday's Pre-Market SessionAcasti Pharma (NASDAQ:ACST), Aptorum Gr (NASDAQ:APM) - Benzinga
Aptorum Group Ltd (NASDAQ:APM) Pleased To Unveil Video Indicating Positive Results On SACT-1 - BP Journal
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models - Business Wire
Sharp thinking in medicine | The Standard - Hong Kong Standard
Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States - BioSpace
Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States - Business Wire
Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM) - GlobeNewswire
USD$90 million initiative between A*Star, Aptorum Group and Aeneas Capital to drive healthcare innovations - Agency for Science, Technology and Research (A*STAR)
Aptorum Group (APM) Stock Price, News & Analysis - MarketBeat
APM Stock Price and Chart — NASDAQ:APM - TradingView
Aptorum Group Limited Announces Closing of Initial Public Offering - Business Wire
Aptorum Group Ltd Stock (APM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):